Gilead secures final regulatory clearance for $115-per-share Arcellx acquisition
Gilead Sciences (NASDAQ:GILD) announced today that it has cleared all necessary regulatory hurdles for its multi-billion dollar acquisition of Arcellx, marking the final steps toward integrating the biotech’s advanced cell therapy platform.

-640x360.webp&w=1200&q=75)








